CooperCompanies Reports Second Quarter Financial Results
CooperCompanies (Nasdaq: COO), a prominent player in the medical device sector, has just reported its financial outcomes for the second quarter of fiscal 2025, concluding on April 30, 2025. This quarter’s results highlight a steady upward trend in revenue and profitability, reflecting the company's ongoing commitment to innovation and share expansion.
Revenue Growth and Performance Metrics
The company achieved a revenue of $1,002.3 million, marking a notable 6% increase compared to the previous year. Breaking it down further, CooperVision (CVI) generated revenues of $669.6 million, an increase of 5%, while CooperSurgical (CSI) saw an 8% increase, reaching $332.7 million. These results demonstrate the effectiveness of the company's strategies to capture market share and underscore its position within the industry.
In terms of profitability, the GAAP diluted earnings per share (EPS) remained consistent at $0.44. However, the non-GAAP diluted EPS rose to $0.96, a growth of 14%, which translates to an increase of $0.11 from the prior year. This growth indicates solid operational efficiency and financial health.
Operating Results and Financial Highlights
Focusing on operational metrics, the gross margin improved to 68%, up from 67% in the same quarter last year, driven by enhanced efficiencies and favorable product mix dynamics. On a non-GAAP basis, the operating margin stood at 25%, higher than the 24% reported in the previous year.
The company reported an interest expense of $24.2 million, down from $28.9 million due to reduced interest rates and lower average debt levels. Furthermore, cash from operations reached $96.2 million, leading to a free cash flow of $18.1 million after accounting for capital expenditures totaling $78.1 million.
CooperVision and CooperSurgical Results
Delving deeper into the contributions of the two operations:
CooperVision (CVI) Performance
CooperVision achieved revenues of $669.6 million, representing a 5% year-over-year growth. The category performance showed strength as daily silicone hydrogel products propelled the overall growth.
CooperSurgical (CSI) Performance
CooperSurgical recorded revenue of $332.7 million, reflecting an 8% increase compared to the prior year. This division's robust growth is attributed to advancements and heightened demand in women's healthcare products.
Looking Ahead: Fiscal Year 2025 Guidance
As part of their ongoing strategy, CooperCompanies has updated its fiscal 2025 guidance, projecting total revenue between $4,107 million to $4,146 million, with organic growth rates expected to be between 5% and 6%. The guidance for CooperVision estimates revenues of $2,759 million to $2,786 million, reflecting organic growth expectations of 6% to 7%. Meanwhile, CooperSurgical anticipates revenues from $1,347 million to $1,359 million, with organic growth rates between 3.5% and 4.5%.
Company Overview and Future Outlook
CooperCompanies is committed to innovation and enhancing patient care within its two divisions. With a workforce exceeding 16,000 and products available in over 130 countries, the company aims to positively impact millions of lives every year through its industry-leading products.
For more information or inquiries, interested parties can contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com
Frequently Asked Questions
What were CooperCompanies' total revenues in Q2 2025?
The total revenues for CooperCompanies in Q2 2025 were $1,002.3 million.
How did CooperVision perform in Q2 2025?
CooperVision reported revenues of $669.6 million, marking a 5% increase year-over-year.
What is the guidance for CooperCompanies' fiscal year 2025?
The guidance for fiscal year 2025 projects total revenues between $4,107 million and $4,146 million.
What factors contributed to CooperCompanies' revenue growth?
Key factors include growth in daily silicone hydrogel products and increased demand in women’s healthcare products.
How does the company plan to enhance its market position?
CooperCompanies plans to focus on product launches, capacity expansions, and strengthening its market share across divisions.
